Skip to main content
. Author manuscript; available in PMC: 2011 Aug 1.
Published in final edited form as: Cancer Res. 2011 Jan 25;71(3):747–757. doi: 10.1158/0008-5472.CAN-10-2267

Figure 6.

Figure 6

Spatial regulation of RhoA activity in invasive p53R172H PDAC cells upon dasatinib treatment in vivo. A and C, Representative in vivo fluorescence images of mutant p53R172H PDAC cells expressing the Raichu-RhoA reporter (green) with SHG signal from host ECM components (purple). B and D, Corresponding in vivo life-time maps demonstrating the presence and absence of RhoA activity in sub-cellular polar regions of cells ± dasatinib, respectively. E, Quantification of fluorescence life-time measurements of RhoA activity within the cell body or poles of p53R172H cells ± dasatinib. (F) Distribution of active and inactive polar regions in p53R172H PDAC cells within the tumor tissue ± dasatinib. Columns, mean; bars, SE. **, P < 0.01